biostudies-literatureJain NNCI NIH HHSAbbVie2095-2103https://www.ebi.ac.uk/biostudies/studies/S-EPMC11827445biostudies-literatureUnknown380(22)<h4>Background</h4>Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.<h4>Methods</h4>We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL. All patients had at least one of the following features: chromosome 17p deletion, mutated <i>TP53</i>, chromosome 11q deletion, unmutated <i>IGHV</i>, or an age of 65 years or older. Patients received ibrutinib monotherapy (420 mg once daily) for 3 cycles, followed by the addition of venetoclax (weekly dose escalation to The New England journal of medicineIbrutinib and Venetoclax for First-Line Treatment of CLL.PMC11827445P30 CA016672Fowler NSasaki KDiNardo CPlunkett WKeating MWierda WKadia TBurger JKanagal-Shamanna RWang XTakahashi KBose PPatel KOhanian MJain NEstrov ZYilmaz MWei CAyala AGarg NFerrajoli ASondermann KJabbour ECruz NGandhi VKonopleva MKantarjian HThompson PAlvarado YPemmaraju NJorgensen JBorthakur GfalseIbrutinib and Venetoclax for First-Line Treatment of CLL.<h4>Background</h4>Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations have indicated potential synergistic interaction of their combination.<h4>Methods</h4>We conducted an investigator-initiated phase 2 study of combined ibrutinib and venetoclax involving previously untreated high-risk and older patients with CLL. All patients had at least one of the following features: chromosome 17p deletion, mutated <i>TP53</i>, chromosome 11q deletion, unmutated <i>IGHV</i>, or an age of 65 years or older. Patients received ibrutinib monotherapy (420 mg once daily) for 3 cycles, followed by the addition of venetoclax (weekly dose escalation to 2019-01-01T00:00:00Z2019 May2026-06-01T08:49:01.991Z2025-04-07T11:28:29.649ZS-EPMC118274453114163110.1056/nejmoa190057410.1056/NEJMoa1900574